4-Hyroxytamoxifen sulfation metabolism

Journal of Biochemical and Molecular Toxicology

Volumn 16, Issue 6, 2002, Pages 279-285

  Chen, Guangping ^a   Yin, Shuhua ^a   Maiti, Smarajit ^a   Shao, Xiuping ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

4 hydroxytamoxifen; Detoxification; Sulfation; Sulfotransferase; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ARYL SULFOTRANSFERASE; CARCINOGEN; DRUG METABOLITE; ESTROGEN SULFOTRANSFERASE; HYDROXYSTEROID SULFOTRANSFERASE; TAMOXIFEN; 4-HYDROXYTAMOXIFEN; DRUG DERIVATIVE; SULFOTRANSFERASE; TRITIUM;

ANIMAL EXPERIMENT; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; CYTOSOL; DRUG DETOXIFICATION; DRUG METABOLISM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; INTESTINE; LIVER CARCINOGENESIS; MALE; NONHUMAN; REVIEW; SULFATION; ANIMAL; ARTICLE; CELL CULTURE; CELL STRAIN CACO 2; CYTOLOGY; DNA ADDUCT; KINETICS; LIVER; METABOLISM; PHYSIOLOGY; RAT; SMALL INTESTINE; SPRAGUE DAWLEY RAT;

ANIMALS; CACO-2 CELLS; DNA ADDUCTS; FEMALE; HUMANS; INTESTINE, SMALL; KINETICS; LIVER; MALE; METABOLIC DETOXICATION, DRUG; RATS; RATS, SPRAGUE-DAWLEY; SULFOTRANSFERASES; TAMOXIFEN; TRITIUM; TUMOR CELLS, CULTURED;

EID: 0036947726     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.10048     Document Type: Review

References (54)

1. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6(6):469-477.
2. Group EBCC. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-1467.
3. Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001;22(6):839-849.
4. Marshall E, Tamoxifen. 'A big deal,' but a complex hand to play. Science 1998;280(5361):196.
5. Fisher B, Costantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, Botel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wormark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
6. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis (Lond) 1993;14:315-317.
7. Fendl KC, Zimniski SJ. Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res 1992;52(1):235-237.
8. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
9. Li XF, Carter S, Dovichi NJ, Zhao JY, Kovarik P, Sakuma T. Analysis of tamoxifen and its metabolites in synthetic gastric fluid digests and urine samples using high-performance liquid chromatography with electrospray mass spectrometry. J Chromatogr A 2001;914(1/2):5-12.
10. De Vos F, Van de Wiele C, Vandecapelle M, Dierckx RA, Slegers G. High performance liquid chromatographic determination of 123-I labeled tamoxifen metabolites in human plasma. Nucl Med Biol 2001;28(3):335-338.
11. Carter SJ, Li XF, Mackey JR, Hanson J, Dovichi NJ. Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry. Electrophoresis 2001;22(13):2730-2736.
12. MacCallum J, Cummings J, Dixon JM, Miller WR. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 2000;82(10):1629-1635.
13. da Costa GG, McDaniel-Hamilton LP, Heflich RH, Marques MM, Beland FA. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 2001;22(8):1307-1315.
14. Shibutani S, Ravindernath A, Suzuki N, Terashima I, et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000;21(8):1461-1467.
15. Cheng RH, Gant TW. Detection of tamoxifen-DNA adducts on lacI genes using DNA polymerase stop assay. Changgeng Yi Xue Za Zhi 1999;22(2):189-196.
16. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, Duffel MW. Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 1998;58(4):647-653.
17. Shibutani S, Ravindernath A, Terashima I, Suzuki N, et al. Mechanism of lower genotoxicity of toremifen compared with tamoxifen. Cancer Res 2001;61:3925-3931.
18. Moorthy B, Sriram P, Pathak DN, Bodell WJ, Randerath K. Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res 1996;56(1):53-57.
19. Marques MM, Beland FA. Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 1997;18(10):1949-1954.
20. Randerath K, Moorthy B, Mabon N, Sriram P. Tamoxifen: Evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis (Lond) 1994;15:2087-2094.
21. Chen G, Battaglia E, Senay C, Falany CN, Radominska-Pandya A. Photoaffinity labeling probe for the substrate binding site of human phenol sulfotransferase (SULT1A1): 7-Azido-4-methylcoumarin. Protein Sci 1999;8(10):2151-2157.
22. Falany CN, Krasnykh V, Falany JL. Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol 1995;52(6):529-539.
23. Ganguly TC, Krasnykh V, Falany CN. Bacterial expression and kinetic characterization of the human monoamine-sulfating form of phenol sulfotransferase. Drug Metab Dispos 1995;23(9):945-950.
24. Falany CN, Wheeler J, Oh TS, Falany JL. Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 1994;48(4):369-375.
25. Falany CN, Comer KA, Dooley TP, Glatt H. Human dehydroepiandrosterone sulfotransferase. Purification, molecular cloning, and characterization. Ann NY Acad Sci 1995;774:59-72.
26. Chen G, Banoglu E, Duffel MW. Influence of substrate structure on the catalytic efficiency of hydroxysteroid sulfotransferase STa in the sulfation of alcohols. Chem Res Toxicol 1996;9(1):67-74.
27. Frame LT, Ozawa S, Nowell SA, Chou HC, DeLongchamp RR, Doerge DR, Lang NP, Kadlubar FF. A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metab Dispos 2000;28(9):1063-1068.
28. Chen G, Rabjohn PA, York JL, Wooldridge C, Zhang D, Falany CN, Radominska-Pandya A. Carboxyl residues in the active site of human phenol sulfotransferase (SULT1A1). Biochemistry 2000;39(51):16000-16007.
29. Nose Y, Lipmann F. Separation of steroid sulfokinases. J Biol Chem 1958;233:1348-1351.
30. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated patients. J Clin Oncol 1993;11:485-490.
31. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
32. King CM. Tamoxifen and induction of cancer. Carcinogenesis 1995;16:1449-1454.
33. Shibutani S, Reardon JT, Suzuki N, Sancar A. Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res 2000;60(10):2607-2610.
34. Umemoto A, Komaki K, Monden Y, Suwa M, Kanno Y, Kitagawa M, Suzuki M, Lin CX, Ueyama Y, Momen MA, Ravindernath A, Shibutani S. Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem Res Toxicol 2001;14(8):1006-1013.
35. Lloyd D. Localization of tamoxifen-induced DNA adducts in rat liver. Trends Pharmacol Sci 2001;22(12): 608.
36. Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol 2001;75(6):375-380.
37. Firozi PF, Vulimiri SV, Rajaniemi H, Hemminki K, Dragan Y, Pitot HC, DiGiovanni J, Zhu YH, Li D. Characterization of the major DNA adducts in the liver of rats chronically exposed to tamoxifen for 18 months. Chem Biol Interact 2000;126(1):33-43.
38. Pathak DN, Pongracz K, Bodell WJ. Activation of 4-hydroxytamoxifen and the derivative metabolite E by uterine peroxidase to form DNA adducts: Comparison with adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 1996;17(9):1785-1790.
39. Beland FA, McDaniel LP, Marques MM. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 1999;20(3):471-477.
40. Osborne MR, Davis W, Hewer AJ, Hardcastle IR, Phillips DH. 4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells. Chem Res Toxicol 1999;12(2):151-158.
41. Osborne MR, Hewer A, Phillips DH. Resolution of alpha-hydroxytamoxifen; R-isomer forms more DNA adducts in rat liver cells. Chem Res Toxicol 2001;14(7):888-893.
42. Boocock DJ, Maggs JL, Brown K, White IN, Park BK. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: A metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 2000;21(10):1851-1858.
43. Umemoto A, Monden Y, Suwa M, Kanno Y, Suzuki M, Lin CX, Ueyama Y, Momen MA, Ravindernath A, Shibutani S, Komaki K. Identification of hepatic tamoxifen-DNA adducts in mice: Alpha-(N(2)-deoxyguanosinyl)tamoxifen and alpha-(N(2)-deoxyguanosinyl) tamoxifen N-oxide. Carcinogenesis 2000;21(9):1737-1744.
44. Kitagawa M, Ravindernath A, Suzuki N, Rieger R, Terashima I, Umemoto A, Shibutani S. Identification of tamoxifen-DNA adducts induced by alpha-acetoxy-N-desmethyltamoxifen. Chem Res Toxicol 2000;13(8):761-769.
45. Umemoto A, Monden Y, Komaki K, Suwa M, Kanno Y, Suzuki M, Lin CX, Ueyama Y, Momen MA, Ravindernath A, Shibutani S. Tamoxifen-DNA adducts formed by alpha-acetoxytamoxifen N-oxide. Chem Res Toxicol 1999;12(11):1083-1089.
46. Shibutani S, Shaw PM, Suzuki N, Dasaradhi L, Duffel MW, Terashima I. Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 1998;19(11):2007-2011.
47. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, Duffel MW. Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 1998;58(4):647-653.
48. Banoglu E. Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens. Curr Drug Metab 2000;1(1):1-30.
49. Flesher JW, Horn J, Lehner AF. 9-Sulfooxymethylanthracene is an ultimate electrophilic and carcinogenic form of 9-hydroxymethylanthracene. Biochem Biophys Res Commun 1998;251(1):239-243.
50. Surh YJ, Liem A, Miller EC, Miller JA. Metabolic activation of the carcinogen 6-hydroxymethylbenzo[a]pyrene: Formation of an electrophilic sulfuric acid ester and benzylic DNA adducts in rat liver in vivo and in reactions in vitro. Carcinogenesis 1989;10(8):1519-1528.
51. Okuda H, Hiratsuka A, Nojima H, Watabe T. A hydroxymethyl sulphate ester as an active metabolite of the carcinogen, 5-hydroxymethylchrysene. Biochem Pharmacol 1986;35(3):535-538.
52. Watabe T, Hiratsuka A, Ogura K, Endoh K. A reactive hydroxymethyl sulfate ester formed regioselectively from the carcinogen, 7,12-dihydroxymethylbenz-[alpha]anthracene, by rat liver sulfotransferase. Biochem Biophys Res Commun 1985;131(2):694-699.
53. Glatt H, Davis W, Meinl W, Hermersdorfer H, Venitt S, Phillips DH. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 1998;19(10):1709-1713.
54. Ramakrishna KV, Fan PW, Boyer CS, Dalvie D, Bolton JL. Oxo substituents markedly alter the phase II metabolism of alpha-hydroxybutenylbenzenes: Models probing the bioactivation mechanisms of tamoxifen. Chem Res Toxicol 1997;10(8):887-894.